Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months
- 1 August 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 23 (8), 1304-1308
- https://doi.org/10.1359/jbmr.080312
Abstract
The duration of the antiresorptive effects of the intravenous bisphosphonate, zoledronate, is not known. Recently, we reported that two annual 4-mg doses of zoledronate suppressed bone turnover and increased BMD in HIV-infected men over 24 mo. We set out to determine the persistence of these effects after two doses of zoledronate. Thirty-three HIV-infected men who completed a randomized trial of 4 mg annual zoledronate (n = 17) or placebo (n = 16) were studied for a further 12 mo, during which time no skeletal therapy was administered. Participants received calcium (400 mg/d) and vitamin D supplements (50,000 IU/mo) for the first 24 mo of the study only. Biochemical markers of bone turnover and BMD were measured every 6 mo. Bone turnover markers were stably suppressed at 24 and 36 mo (12 and 24 mo after the second annual dose of zoledronate, respectively). There were no significant within-group changes in urine N-telopeptide, serum C-telopeptide, and osteocalcin between 24 and 36 mo (p > 0.07), and at each time point, each of the turnover markers was significantly lower in the zoledronate group. There were also no significant between-group differences in the changes in BMD at each site between 24 and 36 mo (p > 0.5), and at each time point, BMD at each site was significantly higher in the zoledronate group. These results suggest that the antiresorptive effects of zoledronate last >12 mo and raise the possibility that zoledronate could be administered less frequently than annually. Randomized trials that address this issue should be performed.Keywords
This publication has 13 references indexed in Scilit:
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureThe New England Journal of Medicine, 2007
- Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic AcidClinical Cancer Research, 2007
- Bone turnover 18 months after a single intravenous dose of zoledronic acidInternational Journal of Clinical Practice, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 2007
- Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled TrialJournal of Clinical Endocrinology & Metabolism, 2007
- Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatiteBone, 2006
- Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention TrialJournal of Bone and Mineral Research, 2004
- Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosisBone, 2004
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With RisedronateJournal of Bone and Mineral Research, 2003
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityThe New England Journal of Medicine, 2002